PT1411938E - Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase - Google Patents

Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase

Info

Publication number
PT1411938E
PT1411938E PT02736467T PT02736467T PT1411938E PT 1411938 E PT1411938 E PT 1411938E PT 02736467 T PT02736467 T PT 02736467T PT 02736467 T PT02736467 T PT 02736467T PT 1411938 E PT1411938 E PT 1411938E
Authority
PT
Portugal
Prior art keywords
cyclopamine
treatment
psoriasis
medication
preparation
Prior art date
Application number
PT02736467T
Other languages
English (en)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1411938(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinan Tas filed Critical Sinan Tas
Publication of PT1411938E publication Critical patent/PT1411938E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
PT02736467T 2001-07-02 2002-04-19 Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase PT1411938E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (1)

Publication Number Publication Date
PT1411938E true PT1411938E (pt) 2005-11-30

Family

ID=21619326

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02736467T PT1411938E (pt) 2001-07-02 2002-04-19 Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase

Country Status (14)

Country Link
EP (4) EP2216022B1 (pt)
JP (3) JP2004536045A (pt)
KR (1) KR20090125833A (pt)
CN (2) CN1525859B (pt)
AT (2) ATE305300T1 (pt)
AU (1) AU2001272892B8 (pt)
BR (1) BR0117063A (pt)
CA (1) CA2452151C (pt)
DE (2) DE60113733T2 (pt)
DK (2) DK1401438T3 (pt)
ES (3) ES2534400T3 (pt)
PT (1) PT1411938E (pt)
RU (1) RU2312661C2 (pt)
WO (2) WO2002078703A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
DE60113733T2 (de) * 2001-07-02 2006-06-29 Tas, Sinan Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
ES2403006T3 (es) * 2005-08-22 2013-05-13 The Johns Hopkins University Antagonistas de la vía Hedgehog para tratar enfermedades
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
ES2547421T3 (es) 2005-10-31 2015-10-06 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar el cáncer
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
MY181496A (en) * 2006-10-31 2020-12-23 Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
AU2008223355B2 (en) 2007-03-07 2014-03-20 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
CN101675054B (zh) 2007-03-07 2014-05-14 无限发现股份有限公司 环杷明内酰胺类似物及其使用方法
ES2610130T3 (es) 2007-12-27 2017-04-26 Infinity Pharmaceuticals, Inc. Métodos para reducción estereoselectiva
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2010080817A2 (en) * 2009-01-06 2010-07-15 Utah State University Carbohydrate-cyclopamine conjugates as anticancer agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
AU2016271468B2 (en) 2015-06-04 2020-01-02 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN117940170A (zh) 2021-09-13 2024-04-26 辛南·塔斯 有效干预人类衰老和衰老疾病及其效果
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768130B2 (en) * 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
AU780358B2 (en) * 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
DE60028411T2 (de) * 1999-10-13 2007-01-04 Johns Hopkins University School Of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
EP1646395B8 (en) * 1999-11-30 2014-12-17 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
DE60113733T2 (de) * 2001-07-02 2006-06-29 Tas, Sinan Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren

Also Published As

Publication number Publication date
EP1561464A2 (en) 2005-08-10
DK1401438T3 (da) 2006-02-13
WO2002078704A1 (en) 2002-10-10
RU2004103074A (ru) 2005-05-10
ES2246011T3 (es) 2006-02-01
CN1522146A (zh) 2004-08-18
AU2001272892B8 (en) 2006-05-04
AU2001272892B2 (en) 2006-03-16
JP2004536045A (ja) 2004-12-02
CN1525859A (zh) 2004-09-01
EP1401438B1 (en) 2005-09-28
JP2010132691A (ja) 2010-06-17
CA2452151C (en) 2012-01-03
RU2312661C2 (ru) 2007-12-20
DE60113733D1 (de) 2006-02-09
CN1525859B (zh) 2010-05-05
JP5424923B2 (ja) 2014-02-26
EP1401438A1 (en) 2004-03-31
EP1561464A3 (en) 2007-04-25
DE60204966T2 (de) 2006-05-18
WO2002078703A1 (en) 2002-10-10
DE60113733T2 (de) 2006-06-29
ATE305300T1 (de) 2005-10-15
KR20090125833A (ko) 2009-12-07
BR0117063A (pt) 2004-07-27
DE60204966D1 (de) 2005-08-11
DK1411938T3 (da) 2005-11-07
ES2250434T3 (es) 2006-04-16
ATE299022T1 (de) 2005-07-15
JP2014028834A (ja) 2014-02-13
WO2002078703A8 (en) 2003-06-12
ES2534400T3 (es) 2015-04-22
EP2216022B1 (en) 2015-01-07
CN1230169C (zh) 2005-12-07
EP2862570A1 (en) 2015-04-22
EP2216022A1 (en) 2010-08-11
CA2452151A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
PT1411938E (pt) Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
PT1202722E (pt) Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
NZ544472A (en) Compounds and therapeutical use thereof
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
DE60100994D1 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
BR0115162A (pt) Tratamentos antitumorais eficazes
HK1068606A1 (en) Novel aminobenzoephenones
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
PT1102586E (pt) Utilizacao de extractos de ginkgo biloba para a preparacao de um medicamento para o tratamento da esclerose lateral amiotrofica
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
AR036877A1 (es) Formulacion farmaceutica
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
HUP0401913A2 (hu) Bromhidrosis kezelésére és megelőzésére szolgáló gyógyszerkészítmény
PT1220676E (pt) Prevencao do cancro colorrectal
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
NO20032799L (no) Nye terapeutiske anvendelser av tienylcykloheksylamin- derivater
ITTV20020159A1 (it) Medicamento fitoterapico per il trattamento delle piaghe da decubito e delle lesioni cutanee in genere ottenuto dalla combinazione di principi attivi contenuti in alcune piante.
AR019703A1 (es) Composicion neuroprotectora para la prevencion y/o tratamiento de alteraciones nerviosas y del comportamiento debidas a estados de ansiedad o depresion